Attached To Cyclopentano-hydrophenanthrene (e.g., Cholesterol, Bile Acid, Steroids, Cholane), Hormone, Or Neurotransmitter, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., T3, T4, Insulin, Human Chorionic Gonadotropin, Intragonadal Regulatory Protein, Mullerian Inhibiting Substance, Inhibin, Epidermal Growth Factor, Nerve Growth Factor, Dopamine, Norepinephrine); Derivative Thereof Patents (Class 424/1.45)
-
Patent number: 7666390Abstract: The present invention relates to diethylenetriamine pentaacetic acid (DTPA) derivates and metal complexes thereof, and radiation sources and contrast agents including the metal complexes. More particularly, the present invention relates to DTPA derivatives, which contain iodine and are useful as contrast agents for diagnosing renal function, metal complexes of the DTPA derivatives with 99mTc, 166Ho, 111In, 90Y, 153Sm, 186Re, 188Re, 68Ga, or 177Lu, which are useful as liquid radiation sources for treating vascular stenosis and contrast agents for diagnosing renal function, and radiation sources and contrast agents including the metal complexes. The DTPA derivatives and metal complexes thereof are safe because the metal complexes are excreted via the kidneys and bladder within several minutes from the time of use as liquid radiation sources for treating vascular stenosis, and are cost-effective because they are potentially useful as contrast agents and as agents for diagnosing renal function.Type: GrantFiled: April 25, 2006Date of Patent: February 23, 2010Assignee: Korea Atomic Energy Research InstituteInventors: Young-Don Hong, Sun-Ju Choi, Ok Ja Choi
-
Patent number: 7579318Abstract: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8 (SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.Type: GrantFiled: December 6, 2005Date of Patent: August 25, 2009Assignees: Centre de la Recherche de la Scientifique, Panomics, Inc.Inventors: Gilles Divita, Frédéric Heitz, Catherine May Morris, Gudrun Aldrian-Herrada
-
Patent number: 7517528Abstract: Epidermal growth factor (EGF) produced by an excretory recombinant approach was tested for its efficacy in treating various skin wounds. In a randomized double blind controlled study, local cream samples prepared with human EGF at a final concentration of as low as 0.02% (g/g) in topically suitable carrier were found to have an enhancing effect on the recovery of diabetes foot ulcers. This promotional effect is statistically significant and has resulted in a reduced mean healing time of over 3 weeks when compared with that of control. Both the 0.02% (g/g) and 0.04% (g/g) human EGF supplemented samples in comparison with control showed a trend of stimulatory effect when a recovery of 50% of an ulcer was considered. The EGF samples were also shown to be highly effective in promoting treatments of wounds resulting from bedsores and surgeries.Type: GrantFiled: March 11, 2003Date of Patent: April 14, 2009Assignee: Bio-Click Technologies, Ltd.Inventors: Wan Keung Raymond Wong, Kat-Hon Lam, Man-Wo Tsang
-
Publication number: 20080279766Abstract: The present disclosure concerns methods of administering and detecting a distinguishable agent in a sample from and assessing the condition of an organ in a subject. In a particular embodiment, the present invention concerns methods of detecting and comparing the cholate shunt, in a subject, preferably in a subject with chronic hepatitis C. In certain embodiments, the methods may comprise obtaining a sample from a subject such as a blood or saliva sample after administering an oral and intravenous dose of a distinguishable agent such as cholate and analyzing the sample clearance of the distinguishable agent from the subject and comparing the clearance levels in order to assess hepatic health. In another embodiment, the methods may comprise analyzing a sample from a subject for the presence of a distinguishable agent such as cholate and applying information obtained from analyzing the presence of the distinguishable agent to determine a treatment for a medical condition of the subject.Type: ApplicationFiled: January 26, 2006Publication date: November 13, 2008Applicant: Regents of the University of ColoradoInventors: Gregory Thomas Everson, Michael Anthony Martucci
-
Patent number: 7404969Abstract: The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver short interfering nucleic acid (siNA). The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).Type: GrantFiled: October 24, 2006Date of Patent: July 29, 2008Assignee: Sirna Therapeutics, Inc.Inventors: Tongqian Chen, Chandra Vargeese, Kurt Vagle, Weimin Wang, Ye Zhang
-
Patent number: 7358223Abstract: Polymers comprising a polyethylenimine, a biodegradable group, and a relatively hydrophobic group are useful for the delivery of bioactive agents to cells.Type: GrantFiled: August 31, 2005Date of Patent: April 15, 2008Assignee: Nitto Denko CorporationInventors: Gang Zhao, Xiaoli Fu, Lei Yu
-
Patent number: 7344700Abstract: Provided is a class of radiolabeled androgen receptor targeting agents (ARTA), useful for prostate cancer imaging and in treating or preventing prostate cancer. The agents define a new-subclass of radiolabeled compounds, which are selective androgen receptor modulators (SARM), which demonstrate antiandrogenic activity of a nonsteroidal ligand for the androgen receptor, and/or which bind irreversibly to the androgen receptor. The present invention further provides methods for a) imaging of cancer in a subject, b) imaging an androgen receptor-containing tissue in a subject, c) in-vivo imaging in a subject, d) treating a subject suffering from prostate cancer, e) delaying the progression of prostate cancer in a subject suffering from prostate cancer, f) preventing the recurrence of prostate cancer in a subject suffering from prostate cancer, and g) treating the recurrence of prostate cancer in a subject suffering from prostate cancer, which comprise using the radiolabeled compounds of the present invention.Type: GrantFiled: February 24, 2003Date of Patent: March 18, 2008Assignee: University of Tennessee Research CorporationInventors: James T. Dalton, Duane D. Miller, Leonid I. Kirkovsky, Arnab Mukherjee
-
Publication number: 20080038191Abstract: Positron emitting compounds and methods of their production are provided. The compounds have the formula: (F)m G (R)n wherein each R is a group comprising at least one carbon, nitrogen, phosphorus or sulfur atom and G is joined to R through said carbon, nitrogen, phosphorus or sulfur atom; G is silicon or boron; m is 2 to 5 and n is 1 to 3 with m+n=3 to 6 when G is silicon; m is 1 to 3 and n is 1 to 3 with m+n=3 to 4 when G is boron; and wherein the compound further comprises one or more counterions when the above formula is charged; and wherein at least one F is 18 F.Type: ApplicationFiled: February 14, 2005Publication date: February 14, 2008Inventors: David M. Perrin, Richard Ting
-
Patent number: 7202330Abstract: The invention relates to compounds having a binding affinity for both the ?v?3 receptor and a (neuro)peptide receptor, in particular the somatostatin receptor, which compound comprises a first peptide part comprising at least once the amino acid sequence Arg-Gly-Asp, and a second peptide part coupled thereto, optionally via a linker, which second peptide part is a (neuro)peptide.Type: GrantFiled: April 26, 2001Date of Patent: April 10, 2007Assignee: BioSynthema Inc.Inventors: Marion DeJong, Eric Paul Krenning, Petrus Martinus Van Hagen
-
Patent number: 7128895Abstract: The use of contrast agents of molecular weight lower than 5000 Dalton and including at least one residue of a biliary acid for the preparation of diagnostic contrast compositions for the microvascular permeability assessment is disclosed.Type: GrantFiled: April 17, 2001Date of Patent: October 31, 2006Assignees: Bracco Imaging S.p.A., The Regents of the University of CaliforniaInventors: Friedrich Cavagna, Timothy P. L. Roberts
-
Patent number: 7101532Abstract: A liposome containing a hydrophobic iodine compound such as a 1,3,5-triiodobenzene derivative having at least one substituent containing 18 or more carbon atoms as a membrane component, and an X-ray contrast medium containing the liposome for use in radiography of a vascular disease and the like.Type: GrantFiled: April 26, 2001Date of Patent: September 5, 2006Assignee: Fuji Photo Film Co., Ltd.Inventors: Kazuhiro Aikawa, Hiroshi Kitaguchi
-
Patent number: 7067109Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: GrantFiled: July 12, 1999Date of Patent: June 27, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
-
Patent number: 7067113Abstract: Screening methods for identifying compounds that bind to or activate (D1 or D5 dopamine receptors individually or in combination) or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of D1 or D5 dopamine receptors or of D1 or D5 dopamine receptor signal transduction pathways and increase D1 or D5 dopamine receptor expression. Pharmaceutical compositions comprising D1 or D5 dopamine receptor agonists, antibodies to D1 or D5 dopamine receptors and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using D1 or D5 dopamine receptors as the target for intervention and methods for treatment of muscular dystrophies are described.Type: GrantFiled: November 18, 2002Date of Patent: June 27, 2006Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Russell James Sheldon
-
Patent number: 6989138Abstract: Radiopharmaceutical compositions which are stabilized by addition of a mixture of a hydrophilic thioether and a hydrophilic 6-hydroxy-chroman derivative.Type: GrantFiled: April 24, 2002Date of Patent: January 24, 2006Assignee: Diatide, Inc.Inventors: John E. Cyr, Daniel A. Pearson
-
Patent number: 6902718Abstract: Radiopharmaceutical compositions which are stabilized by addition of a hydrophilic thioether.Type: GrantFiled: April 24, 2002Date of Patent: June 7, 2005Assignee: Diatide, Inc.Inventors: John E. Cyr, Daniel A. Pearson
-
Patent number: 6887861Abstract: A method for improving intracellular administration of a therapeutic agent is provided comprising: contacting cells with a compound comprising a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and having the cell transport the compound into the cell where the cell metabolizes at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.Type: GrantFiled: November 6, 2000Date of Patent: May 3, 2005Assignee: Asilomar Pharmaceuticals, Inc.Inventors: Gordon Craig Hill, Stephen B. Kahl, Robert R. Webb, Constance A. McKee
-
Patent number: 6881396Abstract: Radiopharmaceutical compositions which are stabilized by addition of a hydrophilic 6-hydroxy-chroman derivative.Type: GrantFiled: April 24, 2002Date of Patent: April 19, 2005Assignee: Diatide, Inc.Inventor: John E. Cyr
-
Patent number: 6818199Abstract: Metal nanoparticles are described that are useful for enhancing the contrast of x-rays or other radiation sources. A method is disclosed whereby the agents are administered intravenously or intra-arterially to detect coronary senses and other vascular features. It is also disclosed how directing moieties attached to the metal particles are used to detect specific targets.Type: GrantFiled: March 8, 2002Date of Patent: November 16, 2004Inventors: James F. Hainfeld, Daniel N. Slatkin
-
Patent number: 6737039Abstract: Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.Type: GrantFiled: December 12, 2002Date of Patent: May 18, 2004Assignee: Praecis Pharmaceutics, Inc.Inventor: Marc B. Garnick
-
Patent number: 6696038Abstract: A biodegradable, novel cationic lipopolymer comprising a branched polyethylenimine(PEI), a cholesterol derived lipid anchor, and a biodegradable linker which covalently links the branched PEI and cholesterol derived lipid anchor. One example of such a novel lipolymer is poly{(ethylene imine)-co-[N-2-aminoehtyl)ethylene imine]-co-[N-(N-cholesteryloxycabonyl-(2-aminoethyl))ethylene imine]} (“PEACE”). The cationic lipopolymers in the present invention can be used in drug delivery and are especially useful for delivery of a nucleic acid or any anionic bioactive agent to various organs and tissues after local or systemic administration. Methods of preparing and using the cationic lipopolymer gene carriers of the present invention to efficiently transfect cells, both in vitro and in vivo, are disclosed.Type: GrantFiled: September 14, 2000Date of Patent: February 24, 2004Assignee: Expression Genetics, Inc.Inventors: Ram I. Mahato, Sang-Oh Han, Darin Y. Furgeson
-
Patent number: 6635234Abstract: Processes for the preparation, prepared solutions, and the use of radium-223 for the treatment of calcified tumors, bone tumors, treatment of bones, bone surfaces and soft tissues is described.Type: GrantFiled: January 3, 2000Date of Patent: October 21, 2003Assignee: Anticancer Therapeutic Inventions ASInventors: Roy H. Larsen, Gjermund Henriksen, Øyvind S. Bruland
-
Patent number: 6613736Abstract: The present invention is a system and method capable of increasing retinal and neural glucose oxidation by enhancing pyruvate dehydrogenase activity and therefore treats retinopathy and central nervous system disorders in both diabetic and non-diabetic patients. The current invention is a system and method of the treating of eye and nerve diseases using insulin pulses to a patient utilizing Chronic Intermittent Intravenous Insulin Therapy to achieve an increase in retinal and neural glucose oxidation by enhancing pryuvate dehydrogenase activity, therefore treating retinopathy and central nervous system disorders in both diabetic and non-diabetic patients.Type: GrantFiled: June 15, 2001Date of Patent: September 2, 2003Inventor: Thomas T. Aoki
-
Patent number: 6540979Abstract: Improved methods for detecting lesions in dense breast tissue are disclosed. The methods of the invention generally feature administration to a subject of an LHRH antagonist in an amount and for a period of time sufficient to reduce the density of breast tissue prior to generating an image of the breast tissue, for example by mammography, to detect a lesion in the breast tissue. Packaged formulations for reducing breast density in a subject prior to generating an image of the subject's breast tissue, comprising an LHRH antagonist packaged with instructions for using the LHRH antagonist to reduce breast density in a subject prior to imaging the breast tissue, are also disclosed.Type: GrantFiled: January 18, 2001Date of Patent: April 1, 2003Assignee: Praecis Pharmaceuticals, Inc.Inventor: Marc B. Garnick
-
Patent number: 6518246Abstract: A pharmaceutical composition and method, for treating human or non-human neoplastic disorders, e.g. colorectal disorders, comprising the administration of pharmaceutically effective amounts of galanin, octreotide and serotonin in a pharmaceutically acceptable carrier. The effective amount is 10 &mgr;g/kg body weight to about 60 &mgr;g/kg body weight of each of the three, preferably about 10 &mgr;g/kg to about 20 &mgr;g/kg of each of the three.Type: GrantFiled: November 28, 2001Date of Patent: February 11, 2003Inventor: Magdy El-Salhy
-
Publication number: 20030003047Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described. Methods for tumor radiotherapy are also provided.Type: ApplicationFiled: April 3, 2002Publication date: January 2, 2003Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: H. W. Strauss, Francis G. Blankenberg, Allan M. Green, Neil Steinmetz
-
Patent number: 6455025Abstract: Polysaccharide-somatostatin analogs of the formula: wherein the somatostatin analog is directly or indirectly coupled from a terminal N-amino group of the somatostatin analog to a polysaccharide, and the polysaccharide-somatostatin analog is provided with an effective negative charge. The compounds are useful in diagnosing and treating cancers.Type: GrantFiled: October 18, 1999Date of Patent: September 24, 2002Assignee: Map Medical Technologies OyInventors: Anders Holmberg, Jan-Erik Westlin, Sten Nilsson
-
Patent number: 6451980Abstract: An immunoassay method including reacting a sample from a patient with a bispecific antibody, wherein the bispecific antibody includes one antibody specific for a compound to be detected and a second antibody specific for a compound foreign to said patient sample, and subsequently reacting the patient sample with a polymer probe, wherein the polymer probe includes a compound recognized by the second antibody in the bispecific antibody complex and further includes at least two detectable signals; the bispecific antibody; and the polymer probe of the immunoassay method are disclosed.Type: GrantFiled: October 6, 1999Date of Patent: September 17, 2002Assignee: Ban-An KhawInventors: Ban-an Khaw, Jagat Narula
-
Publication number: 20020098148Abstract: The present invention relates to a radiolabeled non-steroidal compound having the formula: 1Type: ApplicationFiled: December 15, 1999Publication date: July 25, 2002Inventors: DUANE D. MILLER, LEONID I. KIRKOVSKY, JAMES T. DALTON, ARNAB MUKHERJEE
-
Patent number: 6359111Abstract: A compound comprising a ligand portion which has binding affinity for an opioid receptor, and a therapeutically or diagnostically effective group selected from radionuclide chelating agents, fluorochromes, toxins, drugs, polyboron moieties, proteins, biological response modifiers, chemical moieties capable of binding to other molecules of interest, and radioisotopes selected from therapeutically effective alpha and beta emitters, and diagnostically effective gamma emitters. The compound may be used in a method of treating cancer, and in a method of imaging opioid receptors either inside or outside of the central nervous system.Type: GrantFiled: May 27, 1999Date of Patent: March 19, 2002Assignee: NeoRx CorporationInventors: Damon L. Meyer, Sudhakar Kasina
-
Patent number: 6251363Abstract: Diamine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided.Type: GrantFiled: November 1, 1999Date of Patent: June 26, 2001Assignees: The General Hospital, Northeastern UniversityInventors: David R. Elmaleh, Robert N. Hanson, Choi Sung-Woon